Climb Bio: Deutsche Bank Identifies Entry Opportunity in Biotech Stock with $28 Price Target
Reading Time: 3 minutes
Price target of $28: Why Deutsche Bank currently sees an upside potential of about 185% for Climb Bio. Focus on autoimmune diseases: How the antibodies Budoprutug and CLYM116 specifically target kidney diseases. Solid financial foundation: Why liquidity of €183 million enables uninterrupted research and mitigates sector sell-offs. Focus on B-cell mediated autoimmune diseases Climb Bio (CLYM) is a biotechnology company specialized in clinical research. The business model is based on the development of monoclonal antibodies for autoimmune...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
